Tag Archives: ICE

candlestick chart

5 Tax Bill Conference Report Sections for Agents to Watch

9 Details That Could Be Signs of Life Insurance Fraud

Americo Introduces a Single-Premium Immediate LTCI Policy

A long-running lawsuit between the Trump administration, House Republicans and Democratic attorneys general over billions of dollars of Affordable Care Act public exchange plan subsidies has been settled, according to an agreement filed in federal court Friday.

The settlement agreement, details of which weren’t available in the filings but described as “conditional,” could pave the way for eventual payment of the cost-sharing reduction payments, or CSRs. The CSRs had been paid to health insurers as a way to subsidize some lower-income patients’ insurance co-payments and deductibles, allowing them easier access to health care.

(Related: ACA Mandate Clobbers ACA Subsidy: CBO)

The Trump administration had stopped making the payments, throwing the Affordable Care Act’s markets into chaos and causing premiums to rise, and state Democratic attorneys general continued the legal effort to try and preserve the subsidies.

candlestick chart: Investment Technology Group, Inc.(ITG)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Investment Technology Group Inc. (NYSE: ITG) was downgraded to Market Perform from outperform by KeefeBruyette & Woods.

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

candlestick chart: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

candlestick chart: Vanguard Extended Duration Treasury ETF (EDV)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    The 11 ETF fee cuts unveiled by Vanguard include a significant portion of the issuer's fixed income lineup. All of the following saw annual fees reduced to 0.07 percent from 0.1 percent:

    Vanguard Extended Duration Treasury ETF (NYSE: EDV). Vanguard Intermediate-Term Bond ETF (NYSE: BIV). Vanguard Intmdte Tm Govt Bd ETF (NASDAQ: VGIT). Vanguard Long Term Corporate Bond ETF (NASDAQ: VCLT). Vanguard Lg Term Govt Bd ETF (NASDAQ: VGLT). Vanguard Mortgage Bkd Sects ETF (NASDAQ: VMBS).

    and the Vanguard Short Term Corporate Bond ETF (NASDAQ: VCSH).

candlestick chart: VALE S.A.(VALE)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian spoke about unusually high put options activity in Arconic Inc (NYSE: ARNC) and Vale SA (ADR) (NYSE: VALE).

  • [By Ben Levisohn]

    Mosaic (MOS) tumbled to the bottom of the S&P 500 today after announcing that it would buy Vale’s (VALE) fertilizer unit.

    Getty Images

    Mosaicdropped 1.1% to $27.77 today, while the S&P 500 advanced 0.2% to 2,262.53.

candlestick chart: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

candlestick chart: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Undervalued Stocks To Invest In Right Now

Over the past year, the performance of T. Rowe Price Blue Chip Growth (TRBCX has underscored why it pays to sit tight when a fund with a superior long-term record hits a speed bump. In 2016, as investors turned away from shares of the fast-growing, large-capitalization stocks that Blue Chip targets in favor of more-undervalued fare, the fund lagged the stock market dramatically. Stocks that had previously buoyed the fund, such as Amazon.com and Facebook, were suddenly a drag, says manager Larry Puglia. And energy and utility stockssectors that Blue Chip tends to ignoreperformed exceptionally well.

See Also: Kip 25 Best No-Load Mutual Funds 2017

But these kinds of style shifts dont last forever. Large-cap growth stocks, led by the technology sector, are rebounding this year, and Blue Chip is benefiting. In the first three months of 2017, the fund returned 10.4%, beating Standard & Poors 500-stock index by 4.3 percentage points. Over the past 12 months, Blue Chip, a member of the Kiplinger 25, outpaced the index by nearly a full percentage point. (Prices and returns are through March 31)

Top 10 Undervalued Stocks To Invest In Right Now: L-3 Communications Holdings, Inc.(LLL)

Advisors’ Opinion:

  • [By Paul Ausick]

    Five teams are expected to compete for the contract: Boeing Co. (NYSE: BA) has joined with Saab to offer a clean-sheet design; Northrop Grumman Corp. (NYSE: NOC) has teamed up with BAE Systems and L-3 Communications Holdings Inc. (NYSE: LLL) on another clean-sheet design; Lockheed Martin Corp. (NYSE: LMT) and Korea Aerospace Industries (KAI) are going with a modified KAI T-50; Raytheon Corp. (NYSE: RTN) has joined with Italy’s Leonardo and Canada’s CAE Inc. (NYSE: CAE) on a version of Leonardo’s M-346 trainer that it calls the T-100; and privately held Sierra Nevada has partnered with Turkish Aerospace Industries (TAI) on another clean-sheet design.

  • [By Peter Graham]

    A long term performance chart shows ViaSat, Inc plus mid to large cap communications stockslikeHarris Corporation (NYSE: HRS) and L-3 Communications Holdings, Inc (NYSE: LLL)had been moving in tandem until last yearwhile small cap Gogo Inc has underperformed:

  • [By Peter Graham]

    Headquartered in New York City, large cap L3 Technologies Inc (NYSE: LLL) employs approximately 38,000 people worldwide and is a leading provider of a broad range of communication, electronic and sensor systems used on military, homeland security and commercial platforms. L3 is also a prime contractor in aerospace systems, security and detection systems, and pilot training. The Company reported 2016 sales of $10.5 billion.

Top 10 Undervalued Stocks To Invest In Right Now: Salesforce.com Inc(CRM)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cloud-software leader Salesforce (CRM) – my Top Pick for 2017 among large cap technology stocks — remains well positioned to reap the benefits of the transition away from on-premises solutions.

  • [By WWW.THESTREET.COM]

    “There are two things that mess up your relationships, it’s anger and fear,” explains Robbins. Robbins points to Salesforce (CRM) CEO Marc Benioff as being a total giver, which has set him up for success in business.

  • [By Peter Graham]

    On the earnings call, Ellison noted that the company had surpassed Salesforce.com, inc (NYSE: CRM) in annualized recurring cloud revenue: We are now well on our way to passing them and becoming number one in the enterprise SaaS market.”

Top 10 Undervalued Stocks To Invest In Right Now: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

Top 10 Undervalued Stocks To Invest In Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

Top 10 Undervalued Stocks To Invest In Right Now: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

Top 10 Undervalued Stocks To Invest In Right Now: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Undervalued Stocks To Invest In Right Now: Cemex S.A.B. de C.V.(CX)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cemex SAB de CV (CX) is very interesting at these levels as it seems the market is pricing in a stronger dollar (thereby reducing revenue) and thus lower growth.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.4% Friday to post a new 52-week low of $7.41 after closing at $7.59 on Thursday. The 52-week high is $10.37. Volume was around 8.8 million, about 15% below the daily average of around 9.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.7% Thursday to post a new 52-week low of $7.57 after closing at $7.78 on Wednesday. The 52-week high is $10.37. Volume was around 6.8 million, about 15% below the daily average of around 8.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 1.8% Wednesday to post a new 52-week low of $7.16 after closing at $7.29 on Tuesday. The 52-week high is $10.37. Volume was around 7 million, about 20% below the daily average of around 9.5. The Mexico-based cement company had no specific news.

Top 10 Undervalued Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

Top 10 Undervalued Stocks To Invest In Right Now: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Craig Jones]

    JPMorgan’s analyst Michael Gambardella downgraded Century Aluminum Co (NASDAQ: CENX) from Overweight to Neutral and reduced its price target from $22 to $14.50, citing alumina cost headwinds as the main reason for the downgrade.

Top 10 Undervalued Stocks To Invest In Right Now: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

Top 10 Blue Chip Stocks To Own Right Now

During these busy times, it pays to stay on top of the latest profit opportunities, and today’s blog post is a great place to start.

After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Portfolio Grader recommendations for 113 big blue chips.

Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.

This Week’s Ratings Changes:

Top 10 Blue Chip Stocks To Own Right Now: Abbott Laboratories(ABT)

Advisors’ Opinion:

  • [By Matt Hogan]

    AbbVie has distributed a significant amount of its earnings in the form of dividends (~60 percent) since the company spun off from Abbott Laboratories (NYSE: ABT) in 2013. The company appears to be trading at a 10 percent discount to fair value when applying similar assumptions in the 5-year dividend discount model as shown below.

  • [By Sean Williams]

    Finally, and as the icing on the cake, Wall Street uncovered via a Securities and Exchange Commission filing that Abbott Laboratories (NYSE:ABT) sold 44 million shares of Mylan stock at $41.60, reducing its remaining position in the company to 25.75 million shares, or about 4.8% of its outstanding shares. Considering all the issues Mylan has had recently, the fact that Abbott substantially pared its large holding in the company is a bit worrisome.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Abbott Laboratories (ABT) , Dycom Industries (DY) and Howard Hughes (HHC) .

    Cramer was bearish on Headwaters (HW) , EnergySolutions (ES) , Western Refining (WNR) and Horizon Pharmaceuticals (HZNP) .

Top 10 Blue Chip Stocks To Own Right Now: Allied World Assurance Company Holdings, AG(AWH)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    The insurance firms of Allied World Assurance Company Hldgs Ltd (NYSE: AWH) and Fairfax Financial extended the offering period for purchase of outstanding Allied World shares from June 30 to July 5.

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Friday.

    Douglas Dynamics Inc (NYSE: PLOW) – $0.2350 dividend, 2.9183 percent yield
    Tiffany & Co. (NYSE: TIF) – $0.4500 dividend, 2.6758 percent yield
    PulteGroup, Inc. (NYSE: PHM) – $0.0900 dividend, 1.7078 percent yield
    Leidos Holdings, Inc. (NYSE: LDOS) – $0.3200 dividend, 3.0851 percent yield
    Tupperware Brands Corporation (NYSE: TUP) – $0.6800 dividend, 4.1756 percent yield
    Hudson Pacific Properties Inc (NYSE: HPP) – $0.2000 dividend, 2.36

Top 10 Blue Chip Stocks To Own Right Now: FMC Corporation(FMC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We also want to reiterate our bullish view on the agricultural commodities and the ag-related stocks (e.g., CF Industries Holdings (CF), Mosaic (MOS), Potash Corp. of Saskatchewan (POT), FMC (FMC), AGCO, Deere). Following sharp multi-year declines, trends continue to improve.

  • [By Beth McKenna]

    Most investors interested in gaining exposure to the lithium space should stick with investing in one or more of the large players listed on a major U.S. stock exchange:Albemarle Corporation(NYSE:ALB), FMC Corp. (NYSE:FMC), andSociedad Quimica y Minera de Chile(NYSE:SQM), or SQM. Smaller players are speculative to varying degrees, and most are unprofitable.

  • [By WWW.THESTREET.COM]

    With an improving global economy, now is a great time to be a chemical company, Cramer told viewers, as he reiterated his favorites: Albemarle (ALB) and FMC Technology  (FMC) .

Top 10 Blue Chip Stocks To Own Right Now: iShares MSCI All Peru Capped ETF (EPU)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    ARGT, the lone exchange traded fund dedicated to Argentine equities, is up 19.6 percent year-to-date. That is good for the second-best showing among Latin America single-country ETFs, trailing only the iShares MSCI Capped Peru Index Fund (NYSE: EPU).

  • [By Andrew Efimoff] Related Some Positive Indexing News For A Frontier Markets ETF Why The Frontier Markets ETF Slumped Last Year Status Quo Decisions Would Bode Well For PAK ETF (Seeking Alpha)
    Related EPU Peru ETF Confronts Politics Commodities Call For The Colombia ETF Gra帽a Y Montero May Have Peaked In 2016 (Seeking Alpha) Gainers Pakistan: Global XMSCI Pakistan ETF (NYSE: PAK) is up 5.67 percent after receiving MSCI’s Emerging Markets Index approval. Peru: iShares MSCI All Peru Capped Index Fund(NYSE: EPU) is up 2.15 percent after Kuzynski won Peru’s nail-biting election. Philippines: iShares MSCI Philippines Investable(NYSE: EPHE) is up 2.21 percent after Macquarie Research said President Elect Rodrigo Duterte would lift the Pilipino property market. India: iShares MSCI India ETF (NYSE: INDA) is up 1.96 percent after India’s government relaxed regulation, making it easier for domestic airlines to fly overseas.

    Related Link: Some Positive Indexing News For A Frontier Markets ETF

Top 10 Blue Chip Stocks To Own Right Now: Westell Technologies, Inc.(WSTL)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested small cap high-performance wireless infrastructure solutions stock Westell Technologies (NASDAQ: WSTL) as a buy for our short-term portfolio:

Top 10 Blue Chip Stocks To Own Right Now: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Maxx Chatsko]

    While companies with lower-priced shares are often riskier than those with higher prices, some companies trading under $5 per share have intriguing potential. Investors searching for overlooked growth opportunities should consider industrial biotech BioAmber (NYSE:BIOA), pharmaceutical services company Codexis (NASDAQ:CDXS), and one-trick-pony biopharma Keryx Biopharmaceuticals (NASDAQ:KERX).

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

  • [By Markus Aarnio]

    BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

Top 10 Blue Chip Stocks To Own Right Now: American Financial Group, Inc.(AFG)

Advisors’ Opinion:

  • [By Lee Jackson]

    Aco-chief executive officer of American Financial Group Inc. (NYSE: AFG), Carl Linder, sold a total of 200,000 shares of the property and casualty insurance products provider at prices that ranged from $90.63 to $91.62. The total for the sale was set at $18 million. The shares closed Friday at $91.55, in a52-week range of $65.38 to $92.38. The consensus price target is $95.50.

Top 10 Blue Chip Stocks To Own Right Now: Insperity, Inc.(NSP)

Advisors’ Opinion:

  • [By Lee Jackson]

    Insperity Inc. (NYSE: NSP) also had a large-scale seller on the desk, and it was another well-known hedge fund. Value Act, which also serves as a director at the company, sold a total of 226,000 shares of the stock at prices that ranged from $71.22 to $72.41. The total for the sale was set at $16 million.Insperity provides an array of human resources and business solutions to enhance business performance for small and medium-sized businesses in the United States. The shares closed the day on Friday at $71.85.

Top 10 Blue Chip Stocks To Own Right Now: Xenon Pharmaceuticals Inc.(XENE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 53 percent to $4.68 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

  • [By Jim Robertson]

    On Monday, our Under the Radar Moversnewsletter suggestedgoing long on small cap orphan biopharmaceutical stock Xenon Pharmaceuticals (NASDAQ: XENE):

  • [By Jim Robertson]

    Yesterday, our Under the Radar Moversnewsletter suggested going long on small cap biopharmaceutical stock Xenon Pharmaceuticals Inc (NASDAQ: XENE):

  • [By Lisa Levin]

    Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares dropped 51 percent to $4.80 after the company disclosed that XEN801 did not meet efficacy endpoints in Phase 2 trial.

Top 10 Blue Chip Stocks To Own Right Now: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

stockbroker

While most of the world was consumed with former FBI Director James Comey’s riveting Senate testimony last week, the GOP majority in the House of Representatives quietly prosecuted its war on retirement.

House Republicans under the leadership of Speaker Paul Ryan passed a “Financial CHOICE” Act that would roll back multiple Dodd-Frank protections that were put in place after the 2008 crash. These recent “reforms” mean your retirement savings will be more at risk.

U.S. Speaker of the House Rep. Paul Ryan (R-WI) on June 7, 2017 in Washington, D.C. (Photo by Mark Wilson/Getty Images)

Here are three ways this bill will harm your retirement savings efforts:

1) It peels back banking regulations designed to rein in the banking system. That means banks would be emboldened to take on new risks and endanger the global economy (again). Although a simpler way to regulate banks is to separate ultra-risky bank trading operations from the insured deposit business, the new bill doesn’t take this “Glass-Steagall” approach.

stockbroker: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

stockbroker: Avago Technologies Limited(AVGO)

Advisors’ Opinion:

  • [By Lee Jackson]

    Broadcom Ltd. (NASDAQ: AVGO) also had a huge seller on the trading desk last week. Silver Lake Partners sold a total of 385,797 shares of the supplier of semiconductor connectivity solutionsat a share price of $180.36. The total for the sale was a whopping $69,582,178. The consensus price target for the red-hot technology company is set at $211.68. The shares were trading at $181.94 as the week came to a close.

  • [By Lisa Levin]

    Technology sector was the top gainer in the US market on Friday. Top gainers in the sector included LivePerson, Inc. (NASDAQ: LPSN), Vicor Corp (NASDAQ: VICR), and Broadcom Ltd (NASDAQ: AVGO).

  • [By Chris Lange]

    Broadcom Ltd. (NASDAQ: AVGO) short interest fell to 3.97 million shares in the period, from the previous of 4.43 million. Shares closed most recently at $176.75, in a 52-week range of $114.25 to $179.42.

  • [By WWW.THESTREET.COM]

    The same case is made for Action Alerts PLUS holding Alphabet (GOOGL) and for Lam Research (LRCX) and Broadcom (AVGO) and Growth Seeker holding Amazon (AMZN) –and a host of other high-growth companies.

stockbroker: Gibraltar Industries, Inc.(ROCK)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, basic materials shares fell 0.44 percent. Meanwhile, top losers in the sector included Haynes International, Inc. (NASDAQ: HAYN), down 5 percent, and Gibraltar Industries Inc (NASDAQ: ROCK), down 4 percent.

  • [By Lisa Levin]

    In trading on Friday, basic materials shares fell by 0.82 percent. Meanwhile, top losers in the sector included Gibraltar Industries Inc (NASDAQ: ROCK), down 9 percent, and Yamana Gold Inc. (USA) (NYSE: AUY), down 9 percent.

stockbroker: Allied Motion Technologies, Inc.(AMOT)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggestedsmall cap precision and specialty motion control stock Allied Motion Technologies (NASDAQ: AMOT) as a possible long position:

stockbroker: Reynolds American Inc(RAI)

Advisors’ Opinion:

  • [By Leo Sun]

    With interest rates set to rise this year, many dividend investors are likely worried that their stocks will slip as bond yields become more attractive. While some dividend stocks will inevitably decline, investors can still find some low-risk income plays that have high yields and cheap valuations. Let’s take a look at three such stocks — AT&T (NYSE:T), Cisco Systems (NASDAQ:CSCO), and Reynolds American (NYSE:RAI).

  • [By Ben Levisohn]

    Just before 1pm today, shares of Reynolds American (RAI) took a sudden nosedive on reports that its merger with British American Tobacco (BTI) had “hit a snag” according to StreetInsider.com. Cowen’s Vivien Azer and team still think a deal gets done:

    Getty Images

    Street Insider is reporting that BATS’ acquisition of RAI has “hit a snag,” and that “a potential transaction may be less likely near-term.” We view this source as less credible (vs. a WSJ or CNBC), in particular given the scant level of detail. While the delay in a consummated deal has extended longer than we thought, we still view the deal as likely (85% probability).

    Shares of Reynolds American have dropped 1.3% to $55.47 at 2:26 p.m. today, while British American Tobacco has declined 0.2% to $112.71. Shares of Philip Morris International (PM), which could be interested in an acquisition of Altria Group (MO), have fallen 1% to$90.28 after getting cut toNeutral from Buy at BofA Merrill Lynch, while Altria has risen 0.5% to$67.94 after getting upgraded to Buy from Neutral at Merrill.

  • [By Rich Duprey, Demitrios Kalogeropoulos, and Brian Feroldi]

    It remains true that the tobacco industry will continue coming under pressure from anti-smoking activists, politicians, and regulators who seek to stub out cigarettes further by raising taxes on smokes, but companies such as Altria and Reynolds American (NYSE:RAI) are largely able to offset their impact on profits by raising prices. The ability to command such pricing power without an overly large loss of customers obviously speaks to the addictive qualities of smoking but is also an otherwise enviable position to be in.

micro cap stocks

I believe silver and gold will start moving higher soon so I have been getting my portfolio prepared by researching several mining companies so as to be positioned in the best mining companies to profit from the coming higher metal prices. I think there is a good chance of a surprise summer run but even if that does not happen, we should just stay inside the wide trading range we have been in for quite some time a bit longer and then take off in the fall winter time frame. Either way, for me, it is time to get ready by doing some research. In this first article, I will cover a few of the companies I studied, and I also plan to release many others in future writings. This study to be clear, does not necessarily mean I have bought or love them all, but I at least found them interesting enough to be worthy of being looked at first glance. I would have to say, quite a few of them lived up to what attracted them to me in the first place, but not all.

micro cap stocks: SPDR Blmbg Barclays Intl Trs Bd ETF (BWX)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    DWFI also holds the SPDR Barclays Emerging Markets Local Bond ETF (NYSE: EBND), SPDR Barclays International Treasury Bond ETF (NYSE: BWX) and the SPDR Barclays Intermediate Term Corporate Bond ETF (NYSE: ITR).

micro cap stocks: iShares US Basic Materials (IYM)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Apogee Enterprises strongly outperforming potential performancebenchmarks like theMaterials Select Sector SPDR (NYSEARCA: XLB) and iShares Dow Jones US Basic Materials ETF (NYSEARCA: IYM) albeit that performance has fallen off:

micro cap stocks: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

micro cap stocks: Lockheed Martin Corporation(LMT)

Advisors’ Opinion:

  • [By JPMorgan]

    Lockheed is a leading defense company in an attractive market with a capable management team focused on shareholder returns. The company intends to return roughly all of its cash from ops to shareholders through 2017 (~$5bn annually) through share repurchases and dividends with the current yield of 3.0% leading the group. 

  • [By Money Morning News Team]

    Lockheed Martin Corp.’s (NYSE: LMT) market capitalization is the largest of any defense company – anywhere.

    Lockheed Martin performs research, development, and manufacturing for products in security, defense, and technology.

  • [By Rich Smith]

    A series of tweetstargeting the high cost of Lockheed Martin’s (NYSE:LMT) F-35 stealth fighter jet apparently resulted in LockMart cutting $600 million off the price of a batch of 90 stealth fighters in January. It may have even had something to do with Boeing (NYSE:BA) offering the Navy a steep price cut on a deal to buy a dozen F/A-18 and EA-18G fighters in March. Now, if Boeing could just be convinced to cut the price on its Air Force One contract by a few hundred million, savings resulting from Trump’s defense-spending tweet storms could soon top $1 billion.

micro cap stocks: Whiting Petroleum Corporation(WLL)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, energy shares fell by 1.43 percent. Meanwhile, top losers in the sector included Westmoreland Coal Company (NYSE: WLB), down 9 percent, and Whiting Petroleum Corp (NYSE: WLL), down 7 percent.

  • [By Paul Ausick]

    Whiting Petroleum Corp. (NYSE: WLL) dropped about 6.4% Wednesday to register a new 52-week low of $4.36 after closing at $4.66 on Tuesday. The 52-week high is $13.39. Volume was around 19 million, about 15% below the daily average. The company had no specific news.

  • [By Paul Ausick]

    Whiting Petroleum Corp. (NYSE: WLL) posted a new 52-week low of $4.81 on Friday, down about 7.5% compared with Thursday’s closing price of $5.20. The stock’s 52-week high is $13.39. Volume totaled around 21 million shares, about 5% higher than the daily average. The company had no specific news.

  • [By Jon C. Ogg]

    Whiting Petroleum Corporation (NYSE: WLL) saw its shares rocket up by 30.2% to $12.21 on 79.5 million shares on Wednesday. That represents almost 4 times normal trading volume. Whiting Petroleum has a total market cap of $3.5 billion. The company has a consensus analyst price target of $11.39 and a 52-week trading range of $3.35 to $16.62.